Veeva reaffirms $6 billion 2030 target, says quarter will meet or exceed guidance

Veeva Systems·−0.28% — Veeva Systems, down 0.28 percent as of its last quote, which sells cloud software to the drug industry, put its addressable market at $30 billion at its investor day on November 5↗, up from $20 billion a year earlier, and credited the jump largely to industry-specific AI ¹. Chief executive Peter Gassner then declined to size what that AI might earn. ¹

A $6 billion plan that leaves the AI out

The 2030 goal, a $6 billion annual revenue run rate against roughly $3.7 billion at the July quarter, is built from products Veeva already sells, chief financial officer Brian Van Wagener said ¹. It does not count Falcon, its line of software agents that do work for customers, or Vault AI, priced at 10 percent of a Vault subscription, or Aspen, its customer-relationship-management push beyond drugs ¹. None of the three has a financial target, and Falcon is live at only a few customers, its six- and seven-figure deals still pipeline. ¹

The core has signed paper

An 8-K securities filing dated November 6↗ says the quarter ended October 31 will meet or exceed guidance of $932 million to $935 million in revenue and $417 million to $420 million in adjusted operating income. ²³ The midpoint is about 15 percent growth, cooling from the 17.6 percent of the July quarter. ⁴ Full results and an update to fiscal 2027 guidance, now $1.64 billion of adjusted operating income, come on December 3. ¹

The rest of the core carries signatures: more than 200 customers live on Vault CRM, Veeva's own CRM platform, with 14 of the top 20 drugmakers signed and migrations running into 2029. ¹ UCB, the Brussels drugmaker, committed worldwide on November 4, terms undisclosed. ⁵⁶ IQVIA·−1.32% — IQVIA, down 1.32 percent as of its last quote, the clinical-trials services giant, will run Veeva's clinical-operations software on all new studies within seven months, and Gassner sizes clinical-data sales through contract research organizations above $1 billion. ¹

Six banks repriced the AI layer anyway

On November 6, six banks lifted their targets↗: Jefferies·−2.31% — Jefferies, down 2.31 percent as of its last quote to $375, RBC to $365, BTIG and Needham to $360, UBS and Evercore·−0.17% — Evercore, down 0.17 percent as of its last quote to $325. ⁸⁹ Truist·+0.14% — Truist, up 0.14 percent as of its last quote went to $360 from $305 and Stifel·−0.12% — Stifel, down 0.12 percent as of its last quote to $340. ¹⁰ The shares closed at $306.40 on November 9, up 37.26 percent this year, and the 29-analyst consensus of $323.07 sits just 5.44 percent above the price. ¹⁰

What backs the raises so far are adoptions and demos rather than booked revenue: Roche, the world's fifth-largest drugmaker, is an early Falcon adopter for streamlining health-authority questions, and the widely shared demo of an agent building a clinical study in 45 minutes ran in an article produced with Veeva's sponsorship↗. ¹⁷¹¹

December 3 is the first checkpoint

The arithmetic of the reaffirmed path is modest: $3.7 billion to $6 billion by 2030 takes roughly 12 percent compound growth, against the mid-teens Veeva has printed for two years. ⁴ No filing shows a dollar of Falcon or Vault AI revenue yet; the December 3 guidance update is the first place one could appear, and the checkable question is whether the migration, the CRO data business and IQVIA carry the guide alone ⁴. Six banks raised their targets on a market whose revenue Veeva itself says it cannot size.